Clinical trials: Stage III Lung Cancer
Non-small-cell Lung Cancer
Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)
Randomized Study of Customized Adjuvant Chemotherapy based on BRCA1 mRNA Levels in Completely Resected stages II-IIIA Non-Small-Cell Lung Cancer Patients.
- Trial name
- GECP-SCAT (NCT00478699)
- Testing
- Docetaxel/Cisplatin control, Docetaxel, Gemcitabine/Cisplatin
- Where
- 47 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Spanish Lung Cancer Group
Non-small Cell Lung Cancer Stage III
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
The aim of the study is to investigate the tolerability (how severe the side effects are) and the efficacy (how well the treatment works) when nivolumab is added to the current standard treatment (chemotherapy and radiotherapy)…
- Trial name
- NICOLAS (NCT02434081)
- Testing
- Nivolumab
- Where
- 11 sites in Belgium, Germany and 3 more
- Volunteers
- 94 people
- Sponsor
- ETOP IBCSG Partners Foundation
Carcinoma, Non-Small-Cell Lung
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition to the non-cancer treatments patients would normally receive) is an effective treatment for lung cancer compared to best supportive care…
- Trial name
- MISSION (NCT00863746)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 182 sites in United States, Argentina and 32 more
- Volunteers
- 703 people
- Sponsor
- Bayer
Carcinoma, Non-Small-Cell Lung
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must…
- Trial name
- NCT00656136
- Testing
- BIBW 2992
- Where
- 90 sites in United States, Belgium and 13 more
- Volunteers
- 585 people
- Sponsor
- Boehringer Ingelheim
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Trial name
- NCT02785952
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 1,207 sites in United States, Canada
- Volunteers
- 275 people
- Sponsor
- SWOG Cancer Research Network
Small Cell Lung Carcinoma
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung…
- Trial name
- NCT00143455
- Testing
- Etoposide + cisplatin, Irinotecan + cisplatin
- Where
- 67 sites in Austria, Belgium and 11 more
- Volunteers
- 485 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of Asian subjects with unresectable stage III non-small cell lung…
- Trial name
- INSPIRE (NCT01015443)
- Testing
- Tecemotide, Single low dose cyclophosphamide, Saline
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 285 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Carcinoma
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
This is a study to assess the efficacy and safety of pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV…
- Trial name
- NCT02142738
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 305 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-squamous Non-small Cell Lung Cancer
A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously…
- Trial name
- NCT03329911
- Testing
- EU Avastin®, BAT1706, Paclitaxel
- Where
- 5 sites in China, Mexico and 3 more
- Volunteers
- 651 people
- Sponsor
- Bio-Thera Solutions
Non Small Cell Lung Cancer
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy.
- Trial name
- NCT00095199
- Testing
- Pemetrexed, Cetuximab, Docetaxel
- Where
- 67 sites in United States, Canada
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.
- Trial name
- NCT02418234
- Testing
- mutation detection, ARMS and ddPCR, ctDNA analysis
- Where
- China
- Volunteers
- 314 people
- Sponsor
- First People's Hospital of Hangzhou
Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell…
- Trial name
- NCT01342965
- Testing
- Erlotinib, Chemotherapy
- Where
- 28 sites in China, Malaysia and 1 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally…
- Trial name
- CheckMate73L (NCT04026412)
- Testing
- nivolumab, ipilimumab, durvalumab
- Where
- 183 sites in United States, Argentina and 25 more
- Volunteers
- 925 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
- Trial name
- NCT02273375
- Testing
- MEDI4736
- Where
- 271 sites in United States, Australia and 17 more
- Volunteers
- 1,415 people
- Sponsor
- Canadian Cancer Trials Group
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.
- Trial name
- PACIFIC (NCT02125461)
- Testing
- MEDI4736
- Where
- 236 sites in United States, Australia and 24 more
- Volunteers
- 713 people
- Sponsor
- AstraZeneca
Lung Cancer
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if proton radiotherapy given with standard chemotherapy (such as paclitaxel and carboplatin) can help to control locally advanced NSCLC.
- Trial name
- NCT00495170
- Testing
- Carboplatin, Proton Radiotherapy, Paclitaxel
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, Lung Cancer
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
The purpose of this study is to determine the response rate by RECIST criteria of oral dichloroacetate in patients with recurrent and/or metastatic and pretreated breast and non-small cell lung cancer.
- Trial name
- NCT01029925
- Testing
- Dichloroacetate (DCA)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Small-Cell Lung Cancer
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
- Trial name
- NCT00482014
- Testing
- pemetrexed, cisplatin, carboplatin
- Where
- 11 sites in United States, India
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
- Trial name
- NCT01121393
- Testing
- Gemcitabine+Cisplatin, BIBW 2992
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 364 people
- Sponsor
- Boehringer Ingelheim